TW317487B - - Google Patents
Download PDFInfo
- Publication number
- TW317487B TW317487B TW083104127A TW83104127A TW317487B TW 317487 B TW317487 B TW 317487B TW 083104127 A TW083104127 A TW 083104127A TW 83104127 A TW83104127 A TW 83104127A TW 317487 B TW317487 B TW 317487B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- mixture
- item
- protein
- partial hydrolysate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 235000013350 formula milk Nutrition 0.000 claims abstract description 61
- 239000000413 hydrolysate Substances 0.000 claims abstract description 52
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 34
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 34
- 230000007062 hydrolysis Effects 0.000 claims abstract description 27
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 27
- 235000021119 whey protein Nutrition 0.000 claims abstract description 22
- 239000005018 casein Substances 0.000 claims abstract description 21
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000021240 caseins Nutrition 0.000 claims abstract description 21
- 235000018102 proteins Nutrition 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 229940088598 enzyme Drugs 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 9
- 102000004142 Trypsin Human genes 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 239000012588 trypsin Substances 0.000 claims description 9
- 108090000317 Chymotrypsin Proteins 0.000 claims description 8
- 229960002376 chymotrypsin Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims 2
- 230000008020 evaporation Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 102000014171 Milk Proteins Human genes 0.000 abstract description 13
- 108010011756 Milk Proteins Proteins 0.000 abstract description 13
- 235000021239 milk protein Nutrition 0.000 abstract description 8
- 230000007071 enzymatic hydrolysis Effects 0.000 abstract 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 15
- 239000005862 Whey Substances 0.000 description 12
- 239000003531 protein hydrolysate Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 210000004251 human milk Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 238000010793 Steam injection (oil industry) Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KVYUBFKSKZWZSV-FPLPWBNLSA-N 1-[(9Z)-hexadecenoyl]glycerol Chemical group CCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO KVYUBFKSKZWZSV-FPLPWBNLSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YQDHCCVUYCIGSW-LBPRGKRZSA-N ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate Chemical compound NC(=N)NCCC[C@@H](C(=O)OCC)NC(=O)C1=CC=CC=C1 YQDHCCVUYCIGSW-LBPRGKRZSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Dairy Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
經濟部中央標準局員工消f合作社印製 31748Ϋ at Β7 五、發明説明(J ) 本發明相關領域 « 本發明是有關於牛乳蛋白部份水解產物,以及含有該 水解產物之抗原性降低的嬰兒配方食品(infant formula )的酵素製備方法。 本發明背景資料 許多嬰兒配方食品是以牛乳蛋白質爲主。確實會對牛 乳蛋白過敏的嬰兒需要其中蛋白質已被水解而只含有最少 量殘餘分子結構的嬰兒配方食品。對不會發生過敏的嬰兒 而言,具有抗原性降低之嬰兒配方食品有預防疾病發生的 好處,因爲它可以延遲或預防激敏作用(sensitization ),否則該作用將引起臨床病症或過敏反應。利用蛋白質 水解可使以牛乳蛋白爲主之配方食品的過敏潛在性降低。 爲能完美的接近人乳組成,嬰兒配方食品中的牛乳蛋 白要含有適當比例的乳清蛋白和酪蛋白。雖然有一部份以 完整牛乳蛋白的產品符合所需求的乳清蛋白對酪蛋白的比 例,但幾乎所有市面上銷售之部份水解的嬰兒配方食品都 是以1 0 0 %乳清蛋白爲主。 文獻上所描述的部份水解產物製備方法通常都牽涉到 多重步驟的水解,以及在水解後用以除去酵素和/或殘餘 的蛋白質的物理分離方法。大部份的方法還牽涉到在水解 時的固定p Η値控制。還有就是,除非有加入其他的製程 步驟,否則所得到的水解產物通常會含有高鹽量一這對嬰 兒配方食品會造成配方上的問題,因爲其中礦物質的含量 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3. 10,000 (請先閱讀背面之注意事項再填寫本頁) 訂 317487 A7 B7_ 五、發明説明(2 ) 通常都需控制在一定量內。 美國專利5,0 3 9,5 3 2敘述二步廉的酵素水解 方法以得到所需求特性的水解產物。它同時還敘述了經過 超高溫度(UHT)滅菌之嬰兒配方食品的製備。美國專 利 4,293,571 和 4,981,704 則敍述了以 胰蛋白來製備部份水解產物,它牽涉到後一水解隔膜方法 以將殘餘的蛋白質和酵素分離掉。 蛋白質水解產物一尤其是含有酪蛋白的水解產物,的 一個特徵是會有苦味產生,推定是由於具有疏水性末端基 團之胜肽釋出以致。此外,蛋白質的乳化性質通常也會隨 著水解程度的增加而減少。日本專利1 1 6 0 4 5 8敘述 一種牛乳蛋白水解產物(水解程度在5_2 0%),它具 有表面活性並且在像冰棋淋和奶昔(whipping cream)的 食物中可顯示乳化活性。然而,在像有進行滅菌方法的液 體嬰兒配方食品產品中,對蛋白質水解產物作進一步的變 性作用(denaturation)會使其在乳化液中較不具作用性 。這在產品分離成乳漿和乳酪時會很明顯。就防止曝露於 熱源下的反效果,UHT滅菌作用的高溫一短時間條件通 常會比傳統配方食品的蒸氣消毒器(retort)滅菌作用要 來得適宜。 因此極度希望有部份牛乳蛋白水解產物,它具有抗原 性降低,可提供接近人乳組成物的乳清蛋白對酪蛋白比例 ,改良之滋味,和/或具有改良之乳化活性。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ———1----一1------訂------1 1 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 83. 3.10,000 經濟部中央標準局貝工消贤合作社印製 317487 A7 B7 五、發明説明(3) 本發明概要 本發明是針對蛋白質混合物的部份水解逵物,其中該 蛋白質混合物含有乳清蛋白和酪蛋白,水解產物的水解程 度在4和1 〇 %之間,以及和含有該部份水解產物的嬰兒 配方食品相關。 本發明還和蛋白質混合物之部份水解產物的製備方法 有關,它包括在含水懸浮液中,使乳清蛋白和酪蛋白的混 合物與含有至少1 8 0 0單位/毫克USP胰蛋白酶和至 少3 5 0單位/毫克USP胰凝乳蛋白酶的酶混合物接觸 ,以得到水解程度在4和10%之間。 本發明的詳細說明 本發明提供一種包含有乳清蛋白和酪蛋白之混合物的 部份水解產物一它適用於具有抗原性降低之營養產品的製 造,以及提供其製備方法。和先前技術的部份蛋白質水解 產物相比,本發明的部份水解產物的乳清蛋白/酪蛋白比 例要較接近人乳。此外,本發明的水解產物較宜有改良的 滋味和改良的乳化活性。 本發明方法可使用其中乳清蛋白和酪蛋白比例較宜接 近人乳之混合物的起始原料來進行。蛋白質混合物較宜含 有約6 0至8 0%的·乳清蛋白和約4 0至2 0%的酪蛋白 ,更適宜爲約4 0至6 0%的乳清蛋白和約6 0至4 0% 的酪蛋白。酪蛋白和乳清蛋白百分比是表成以重量爲基準 。乳清蛋白的來源可以是乳酪製造時得到的乳清,尤其是 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83.3. 10,000 (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消f合作社印製 317487 at B7 五、發明説明(4) 以凝乳劑(rennet)來使酪蛋白凝聚而得到的甜乳清。乳 清蛋白也可以超過濾得到之含有約3 5 _ 8 0 %蛋白質的 濃縮形式(UF乳清)來使用。該乳清原料可選擇性地以 離子交換和/電透析法來進行聡礦物質作用(ED乳清) 。酪蛋白來源可以是酸性酶蛋白或無脂牛乳固體( NFDM)。乳清蛋白和酪蛋白可以濃縮液或粉末形式來 使用。基於本發明的目的,將蛋白質稀釋成,或重新組構 成(reconstitute )爲毎升含有約1 0至6 0克蛋白質 ,較宜爲每升含有約4 0茔6 0克蛋白質的溶液。
本發明方法使用胰蛋白酶和胰凝乳蛋白酶的混合物, 其酵素特性爲互補的。酵素混合物較宜不受其它蛋白酶, 比如羧肽酶A和B或亮胺酸胺肽酶,的汙染。混合物中的 胰蛋白酶含量等於或大於8 0 0 USP單位/mg,較宜 等於或大於1 0 0 0 USP單位/mg,更適宜等於或大 於1 8 0 0USP單位/mg。一個USP胰蛋白酶單位 爲在5分鐘的化驗時間,pH爲7. 6,25土0. 1°C 和N_苯甲醯基一 L —精氨酸乙酯氯化氫(BAEE>用 作底質的條件下,可引起每分鐘有0. 003吸收變化的 活性。 混合物中的胰凝乳蛋白海含量等於或大於1 5 0 USP單位/mg,較宜等於或大於2 0 0USP單位/ mg,更適宜等於或大於3 5 0USP單位/mg。一個 u S P胰凝乳蛋白酶單位爲在5分鐘的化驗時間,P Η爲 7 · 6,25士0_ 1°C和Ν —乙醯基一L -精氨酸乙酯 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3.10,000 (請先閲讀背面之注意事項再填寫本頁) 訂 Μ ! 317487 at B7 五、發明説明(5 ) (ATE E )用作底質的條件下,可引起每分鐘有 0.0075吸收變化的活性。 ^ 適用於本發明的酶,其市售廠商包括有位在美國,康 乃迪克州,Danbury 的 Novo No'r disk Bioindustrials 公 司(尤其是其PEM 25 0 OS ).:美國紐約州紐約市的Enzyme Development公司:美國紐約州Purchase的Intergen公司 :美國威斯康辛州Waunakee的Scientific Protein實驗室 Ο 要獲得具有所需求物性的水解產物,則在胰蛋白酶和 胰凝乳蛋白酶的混合物中,胰蛋白酶對胰凝乳蛋白酶的比 通常須在約1. 3至約18的上述USP單位之間,較宜 在約1. 3至約10之間,更適宜在約4至6至間。基於 本發明目的,酶的混合物通常是,根據進行水解之全部蛋 白質重量爲基準,以約0. 4重量%至約1. 2重量%的 量,較宜爲約0. 6重量%至約0. 8重量%的量,來使 用。 經濟部中央標準局員工消资合作社印製 一個在水解前的選擇性初步步驟爲對蛋白質溶液作預 加熱以確定乳清蛋白部份一比如血清蛋白(BSA)和免 疫球蛋白(尤其是IgG),有進行變性作用。當以免疫 化學方式來評估時(如底下所說明的),該步驟通常可導 致殘餘抗原性的降低。該預處理步驟的進行,通常是加熱 至約7 5 °C和約8 5 °C之間,並維持在該溫度約1 〇分鐘 至3 0分鐘。水解本身通常是在約3 0°C至約5 0°C之間 的溫度進行約2至6個小時,較低的溫度上下限相當於較 83. 3. 10,000 (請先聞讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐〉 A7 B7 317487 五、發明説明(6 ) 長的時間上下限,反之亦然。在水解當中,通常並不需要 固定pH在一定値,因爲水解通常是在6. 5 - 6 . 8之 間的p Η値進行,故無需另外的p Η控制。但無論有無 ΡΗ控制,pH値仍應維持在杓6. 5至8. 0之間。 無論水解條件爲何,水解產物較宜進行另外的酶去活 化步驟。該酶的去活化可以是一個熱處理,它包括加熱至 約8 5°C的溫度,並維持在該溫度約1 0分鐘。另一種選 擇則是,酶可在超高溫度下進行滅菌(比如在約1 3 0°C 中約4 5秒)以使去活化,然後產品以液態來貯存。水解 產物也可以蒸發或噴灑乾燥法以使乾燥的方式來進行濃縮 0 爲監控水解進行的程度,使用美國藥典(US P )的 甲醛滴定法,其中胜肽鍵在水解當中所增加的自由胺基可 由氫氧化鈉的滴定來估計。水解程度在4%和10%之間 ,較宜在5 %和7 %之間。本發明的一個優點爲水解程度 要比某些先前方法所達到者要低;然而仍可在抗原性上獲 得明顯的降低。 使用大小互斥層析法(S E C )來測定水解產物的胜 肽分子量分布。使用一支維持在3 7 °C,並使用TFA和 乙腈在KC1中的溶液以0. 7ml/分的速度進行沖提 的TSK G — 2 0 0 0 SWXL管柱,水解產物中的 胜肽是根據其中的分子大小來分離。在2 1 4 nm時的吸 收相對滯留時間是以UV偵測器來產生,並和標準蛋白質 及已知分子量的胜肽作比較。本發明之部份水解產物的平 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 尊! 經濟部中央標準局員工消費合作社印製 83. 3.10,000 經濟部中央標準局負工消费合作社印製 分子量(克/葚:§:) MW>5000 5000>MW>3000 3000>MW>2000 2000>MW>1000 1000>M¥>500 MW>500 317487 五、發明説明(7) 均分子量較宜爲2,0 〇 〇,最大分子量爲1 9,0 〇 〇 ,並包括如下列分布,以其分子量爲函數,的胜肽: %分子量分布 8.2 14.5 15.8 26.2 17.8 17.5 本發明的水解產物較宜沒有可偵測之完整牛乳蛋白質 存在。水解產物中是否有完整牛乳蛋白質的存在,可以十 二硫酸鈉一聚丙烯醯胺凝膠電泳法(SDS — PAGE) 來證明。SDS — PAGE是以4至2 0梯度%的三甘胺 酸(Trisglycine )凝膠來進行。以SDS來處理1 5微 米經水解過的蛋白質,以2 -巯基乙醇還原,加熱並塗覆 至各個小徑(丨ane)上。在電泳分離完成後,以銀來對凝 膠染色以使殘餘的胜肽顯示出來。利用同一個凝膠,以5 微克的未水解蛋白質起始物來作直接的比較。 使用酶一連結的免疫附著(immunosorbent )分析法 (EL I SA)來測定水解產物的殘餘抗原性。將濃度落 在分析所建議之線性劑量反應範圍內的未水解牛乳蛋白質 固定在固相中。水解產物的製備也是以類似固定的方式來 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) -訂 83. 3.10,000 10 - A7 B7 五、發明説明(8 ) 進行。接著,利用兔子抗牛乳蛋白和對兔子I g G有共範 反應性的酶所作的一系列培育,則可顯示出其中是否有抗 原性可辨認之蛋白質和胜肽的存在。在以質量爲基準下, 比較水解產物和未水解蛋白質起始物所得到的結果。本發 明水解產物的抗原性降低至少約有8 5%,較宜至少約有 8 5%,更適宜至少約有9 0%,最適宜至少約有9 5% Ο 本發明的水解產物可適用於嬰兒配方食品,可以配方 食品工業所通常使用的單元操作方式來加工。這類配方食 品和相對應的未水解蛋白質在抗原性降低上的比較是由上 述的ELISA方法來測定。 和相對應的未水解蛋白質混合物相比,以本發明水解 產物製備的本發明嬰兒配方食品在抗原性降低上至少約有 8 0%,較宜爲至少約有8 5%,更適宜爲至少約有9 0 %,最適宜爲至少約有9 5。本發明的嬰兒配方食品可以 是粉末,濃縮液或隨時可使用的液體等形式。 經濟部中央標準局員工消費合作社印製 此外,和以部份水解乳清蛋白製成之相對應嬰兒配方 食品相比,本發明的嬰兒配方食品的味道有改良。 本發明嬰兒配方食品含有設計用來滿足嬰兒在養份上 需求的成份。因此,除了本發明的部份水解產物,一個典 型的嬰兒配方食品含有脂質來源,碳水化合物來源和其他 像維生素和礦物質的養份。通常會將動物油,植物油,澱 粉,蔗糖,乳糖和/或玉米糖漿固體加至嬰兒配方食品中 ,以供應部份或全部的上述養份。 83. 3.10,000 (請先閲讀背面之注意事項再填寫本頁j 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 11 經濟部中央標準局員工消费合作社印製 317487 A7 B7 五、發明説明(9 ) 本發明的嬰兒配方食品較宜爲養份完整的(nutritionally complete ) 。 所謂 、養份完整 # 是指在展延的期 間內,組成物含有足以維持人體健康生活所需的養份。 每1 0 0千卡的全部配方食品含有的部份蛋白質水解 產物量通常約1. 8克至約4. 5克:每100千卡的全 部配方食品含有的脂質來源量通常爲約3. 3克至約6克 ;每1 0 0千卡的全部配方食品含有碳水化合物來源量通 常爲約7克至約14克。 嬰兒配方食品中的碳水化合物來源可以是任何技術上 已知適用於嬰兒配方食品的合適碳水化合物。典型的碳水 化合物包括蔗糖,果糖,葡萄糖,麥芽糖糊精,乳糖,玉 米糖漿,經修飾的玉米澱粉,經修飾的茨粉(13?丨(^3 5-t a r c h ),米麩,大豆麩等等。 t 嬰兒配方食品中的脂質來源可以是任何技術中已知適 用於嬰兒配方食品的脂質或脂肪。典型的脂質源包括牛乳 脂肪,紅花油,蛋黃脂肪,橄欖油,花生油,棕櫚油,棕 櫚仁油,大豆油,向日葵油,魚油和其衍生出來的餾分一 比如棕櫚油酸甘油酯,中間鏈甘油三酸酯(MCT),以 及脂酸的酯類一其中脂酸爲花生四烯酸,亞油酸,棕櫚酸 ,硬脂酸,廿二碳六烯酸,廿碳五烯酸,亞麻脂酸,油酸 ,月桂酸,癸酸,辛酸,己酸等等。預期各種油類的高油 酸鹽形式,比如高油酸鹽的向日葵油和髙油酸鹽的紅花油 ,也適用於此。中間鏈的甘油三酸酯含有濃度通常較傳統 油類要高的辛酸和癸酸,也就是說,全部脂酸含量中大約 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 83.3.10,000 (請先閲讀背面之注意事項再填寫本頁) 、?τ 經濟部中央梯绛扃員工消费合作社印裝 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇χ297公釐) 83. 3.10,000 A7 B7 五、發明説明(1〇) 有3/4爲辛酸,1/4爲癸酸。 含有本發明部份蛋白質水解產物的嬰兒E方食品可選 擇性地補充有各種的自由氨基酸,以提供營養均衡的氨基 酸含量。道類自由氨基酸的例子包括L —色氨酸,L 一甲 氨酸,L —胱氨酸,L —酪氨酸,和L —精氨酸。 吾人了解,含有所有維生素和礦物質的營養完整組成 物,對日常飲食是很重要的,並且這些組成應該是以營養 顯著的量存在。技術熟練人士將可看出,已對某些已知對 正常生理作用爲必須的維生素和礦物質建立了最低的需求 量。有經驗的人也了解,需提供適當之額外量(過剩)的 維生素和礦物質成份,以便能補充這類組成物在處理和貯 存時的一些損失。 要選擇可使用於嬰兒配方食品的特定維生素或礦物質 化合物時,需考慮到化合物其和處理及架貯時相容性的化 學本性。 t 礦物質,維生素和其他選擇性可存在於本發明組成物 之養份的例子包括維生素A,維生素B6 ,維生素312, 維生素E,維生素K,維生素C,葉酸,硫胺素,肌醇, 核黃素,菸鹼酸,生物素,泛酸,膽素,鈣,磷,碘,鎂 ,銅,鋅,猛,氯,鉀,鈉,硒,鉻,鉬,牛磺酸,和L 一肉鹸。磺物質通常是以鹼的形式加入。除了相容性和安 定性的考慮外,特定磺物質和其他維生素的存在及量會隨 所設計的嬰兒人口而有些變化。 本發明的嬰兒配方食品通常也含有乳化劑和安定劑, -13 - ---ml--:----一:------訂------II (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A7 _B7____ 五、發明説明(n) 比如黃豆卵磷脂,鹿角菜等等。 本發明的嬰兒配方食品還可選擇性含有真它可能有益 處的物質,比如乳酸牖鐵素(Uctoferrin ),核苜酸, 核苷,免疫球蛋白等等。 本發明液體嬰兒配方食品的滲透性(當準備要使用時 )通常約爲1 0 0至5 0 0 ioOsm/公斤水,更通常約爲 2 0 0至5 0 OmOsm /公斤水。 如有需要,本發明的嬰兒配方食品可以技藝上熟知的 技術,比如像高壓滅菌法或蒸氣消毒法(retorting )等 等的熱處理來進行滅菌。 本發明的嬰兒配方食品可以技藝上已知可用來貯營養 配方食品的任何型式容器,比如玻璃,裝塡紙袋,塑膠, 經塗覆的金屬罐等等,來加以包裝。 以下的實施例用來說明本發明,但不可解讀爲對其的 限制。 寅施例1 蛋白質爲在5 0°C時濃度爲4 一 6 %的可溶解蛋白質 。這相當於1 0 — 2 5 %的固體,視所使用蛋白質種類而 定。預加熱處理包括固定在7 5 °C達3 〇分鐘。使混合物 冷卻至5 0°C,並加入酶的混合物。可在3 0 — 5 0 °C的 溫度範圍內進行2 — 6小時的水解作用。水解的時間和溫 度爲彼此相關的,較低的溫度上下限相當於較長的時間上 下限,反之亦然。在水解期間對混合物的P Η値可,也可 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) 83. 3. 10,000 1.1-ΊΚ--:----ί:------tr------Μ 1 (請先閣讀背面之注意事項再填寫本頁) 14 317487 A7 B7__ 五、發明説明(12) 不用加以控制。爲使酶去活化,使水解產物接受注入溫度 爲1 3 5°C的蒸氣達4 5秒。該高溫步驟連崗預加熱處理 和酶的水解可生成抗原性降低的水解產物。如有需要,可 以氫氧化鉀將PH値調整到至少爲6. 6,以防止在熱處 理時有熱凝結產生。 實施例2 進行如實施例1的製程,不同的是在進行10分鐘的 8 5°C預加熱處理之前,先以KOH將p Η値調整至 7 . 5。爲使酶去活化,使部份水解產物加熱至8 5 °C並 維持在該溫度達10分鐘。如同寅施例1,在後續步驟開 始之前,先將pH値調整到至少爲6. 6。 在下表中顯示出不同的處理變數以說明根據實施例1 和2之水解產物的製備。在所有的情形中,乳清蛋白:酪 蛋白的重量比爲8 0 : 2 0。 (請先閲讀背面之注意事項再填寫本頁) 訂 -典! 經濟部中央標準局員工消費合作社印製 83.3. 10,000 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -15 - 五、發明説明(13) A7 B7 經濟部中央標準局員工消f合作社印製 變數 寅施例 %D . Η · 抗原性降低% (水解產物) 胰蛋白酶對 1.3· 胰凝乳蛋白酶比 5.3 2 6.77 92.5 2 6.50 94 . 3 8.8 2 7.24 93.7 酶的濃度 0.8 (蛋白質%) 0 . 6 2 5 . 50 92.7 2 4.88 91 · 3 0.4 2 4 . 72 . 91 . 3 水解時間 2 (小時) 2 1 4 . 53 90.6 2 4.55 91.8 3 1 4.57 92 . 4 3 2 5 . 48 93.9 4 1 5 . 35 92.4 4 2 6 . 50 94 _ 3 6 2 6.73 94.6 水解溫度(°C ) 30 2 4 . 58 89.9 40 2 5.71 91.6 50 2 5.76 94.6 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3. 10,000 (請先閲讀背面之注意事項再填寫本頁) ,βτ 屬! A7 B7 五、發明説明(14) 實施例3 對一個液體嬰兒配方食品,將預先溶解的乳糖和礦物 質加入實施例1的部份水解產物。在金靥板型的熱交換器 上使混合物加熱至7 0°C。接葦加入含有棕櫚油酸,向日 葵油,花生油,大豆油,卵磷脂,甘油脂及甘油二脂的脂 肪和脂溶性維生素。油類加入混合物之前已先熔解。在預 加熱至約7 5 °C時,直接注入蒸氣來使混合物加熱至 1 4 OeC達4 5秒,並以金屬板冷卻器來使冷卻至7 0°C 。然後接著是兩階段的均貧化,首先在1 7 5巴,接著在 3 5巴。然後以金靥板冷卻器來使混合物冷卻至5 — 7°C ,並貯存於中間反應貯存槽,水溶性維生素是在此加入。 該方法的整體產品的熱凝結時間超過3 0分鐘。以傳統的 高溫蒸氣系統來對產品進行滅菌。 液體具有下列的組成物: (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消费合作社印製 胜肽 1 . 6 5 % 脂肪 3 . 6 0 % 碳水化合物 6 . 5 2 % 礦物質 0 . 4 8 % 維生素 微量 實施例4 對另一個液體嬰兒配方食品?以來自寅施例2的水解 產物來進行如寅施例3的製程,不同的是直接注入的蒸氣 -17 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3. 10,000 317487_%_ 五、發明説明(15) 溫度爲12 1°C,液體是在14 5°C進行4. 9 7秒的滅 菌,並以無菌包裝的容器內。組成物和實施例3者相同。 實施例5 對嬰兒配方食品,使用來自實施例1或2的部份水解 產物來進行如實施例3的製程,不同的是,產品在1 2 5 巴和5 0巴的兩階段均質化步驟之前未接受蒸氣注入的溫 度處理。在進行噴灑乾燥前,可使粉末底質蒸發成5 0% 的固體。 粉末具有下列的組成物: (請先閲讀背面之注意事項再填寫本頁)
胜肽 13.1 % 脂肪 2 8.6 % 碳水化合物 5 1.8 % 礦物質 3 . 8 % 維生素 0 . 2 % 水份 2 . 5 %
1T 經濟部中央標準局員工消費合作社印製 至 IX 例 施 寅 如 之 備。 製性 法原 方抗 明之 發低 本降 由出 ,現 的顯 示品 顯食 所方 表配 下兒 如嬰 的 5 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3.10,000 -18 - 五、發明説明(16) A7 B7 產品形式(乳清蛋白:酪蛋白 實施例~ 抗原性 的重量比,蛋白質來源) 減少% 液體(80:20,UF'乳清,NFDM'_) 寅施例1 , 4 92.4 液體( 80:2 0,UF乳清,NFDM) 寅施例2 , 4 94 . 3 液體(80 : 2 0 , UF乳清,NFDM) 實施例1 , 3 92.1 液體(8 0 : 2 0 , U F乳清,酪蛋白) 實施例1 , 4 81.4 液體(6 0 : 4 0,UF乳清,NFDM) 實施例1 , 4 87.8 液體(6 0 : 4 0 , E D' …乳清,N F D Μ ) 實施例1 , 4 94 . 6 粉末(80:20 ,UF 乳清,NFDM) 實施例2 , 5 92.3 經濟部中央標準局員工消費合作社印製 'U F =超過濾的 __N F DM二無脂乾燥奶粉 …· E D =電泳 實施例6 (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS〉A4規格(210X297公釐) 83. 3. 10,000 -19 - 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(17) 一個包括4 0名成員的消费者小組對大致如實施例4 說明之本發明嬰兒配方食品和具有類似成份i但不同的地 方在蛋白質成份爲部份水解之1 0 0 %乳清蛋白一的市售 嬰兒配方食品(由位在美國加州Glendale的Carnation公 司出品的Good StarTM鐵强化嬰兒配方食品)作評估和比 較。樣品是在室溫下提供的,並由小組成員評估。利用9 分的喜歡程度(9 =非常喜歡,1=非常不喜歡)來對嬰 兒配方食品的特定和味覺特性一比如苦味,餘昧’ 口感, 以及整體滋昧分數。 結果如下表所示。 本發明配方食品 Good S t a 外觀 7 . 3 6.7' 滋味 4.0 3 . 3* 滋味强度 4.5 4.0 甜度 4.8 4.1* 在奶油中(buttery) 5.0 4 . 5 在肉中 4.4 4.1 苦味 3 . 6 3.6 餘味 3 . 0 3 . 7' 整體表現 4.2 3.6' 喜歡程度 68% 32% 評語 苦味8¾ 苦味18¾ 顏色很醜8 % 表示在9 5 %可靠範圍內,樣品彼此間有顯著的差異。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 83. 3.10,000 II :--.T L ^---Ί------訂- ------名 (請先閲讀背面之注意事項再填寫本頁) 20 A7 B7 五、發明説明(18) 比起Good Start,本發明的嬰兒配方食品要受歡迎得 多。參與者的評論指出,本發明嬰兒配方食品之所以會比 Good Start受歡迎,主要是因爲Good Start的苦味本性。 藉著特別參考其較佳體系,已對本發明作詳細說明, 但要了解的是,只要在本發明的精神和範圍內即可進行變 動和變化。 (請先閲讀背面之注意事項再填寫本頁) 訂------名丨 經濟部中央橾準局員工消f合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 21 83. 3.10,000
Claims (1)
- 告 ABCC # 附件一(A ): 第83104127號專利申請案 中文申請專利範圍修正本 ' 民國85年12月修正 1 . 一種蛋白質混合物之部份水解產物,其中該蛋白 質混合物係含有6 0至8 0重置%之乳清蛋白及4 0至 2 0重量%之酪蛋白,且該部份水解產物係具有(1 )水 解程、度介於4至10%之間,(2)藉由ELISA測量 ,相對於其相對應之未水解蛋白質混合物,抗原性係降低 80 — 99%,及(3)平均分子量爲2,000,最大 分子量爲1 9,0 Q Q,且以其莫耳質量爲基準,其肽分 佈係如下所示: 經濟部中央標準局員工消費合作杜印製 %分子量分佈 8.2 14.5 15.8 26 . 2 17.8 17.5 (請先閱讀背面之注意事項再蜞寫本頁) 分子暈(克/莫瓦) MW>5000 5000>MW>3000 3000>MW>2000 2000>MW>1000 1000>MW>500 MW>500 該部份水解產物之製備係藉由於6 〇至9 〇 〇c之溫度下先 期預熱該蛋白質混合物達1 0至5 0分鐘且於3 〇至5 0 °0之溫度及pH値介於6 . 5至8 . 〇之條件下,令該蛋 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-1 - ABCD 017487 六、申請專利範圍 (請先閲讀背面之注意事項再填寫本頁) 白質混合物與一酶混合液於水溶性懸浮液中相接觸達2至 6小時,以使該蛋白質混合物之水解程度達4至1 0 %、 其中該酶混合液係'包含至少1 8 0 OUSP胰蛋白酶單位 / m g及至’少3 5 OUSP胰凝乳蛋白酶/ mg,且該胰 蛋白酶對胰凝乳蛋白酶之USP單位比係介於1.5至 1 〇之間,且隨後該酶混合液之去活化係藉由於7 0至 9 0°C之溫度下加熱該部份水解產物達5至2 0分鐘,或 於1 1 0至1 4 0°C之溫度下加熱該部份水解產物達3 0 至6 0秒。 2 .如申請專利範圍第1項之部份水解產物,其係具 有藉由E L I S A測量,相對於其相對應之未水解蛋白質 混合物,抗原性降低8 5 - 9 9%。 3 .如申請專利範圍第1項之部份水解產物,其係具 有藉由EL I SA測量,相對於其相對應之未水解蛋白質 混合物,抗原性降低9 Q — 9 9%。 經濟部中央標準局员工消費合作社印製 4 .如申請專利範圍第1項之部份水解產物,其係具 有藉由E L I S A測量,相對於其相對應之未水解蛋白質 混合物,抗原性降低9 5_9 9%。 5 .如申請專利範圍第1項之部份水解產物,其中該 酶混合液之用量係基於混合物中蛋白質之重量爲介於 0 . 4至1 . 2 %之間。 6 .如申請專利範圍第1項之部份水解產物,其中於 額外之步驟中係藉由蒸發或噴轎乾燥以自該部份水解產物 中除去水。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)_ 2 _ ABCD 317487 六、申請專利範圍 7 .—種嬰兒配方食品,其係包含如申請專利範圍第 1項之部份水解產物,以及慣用之碳水化合物,脂質,礦 物質和維生素。^ 8 .如申請專利範圍第7項之嬰兒配方食品,其係經 消毒滅菌。 9 .如申請專利範圍第7項之嬰兒配方食品,其係經 高溫蒸氣滅菌。 10 .如申請專利範圍第7項之嬰兒配方食品,其係 呈粉末之型式。 1 1 .如申請專利範圍第7項之嬰兒配方食品,其係 具有藉由E L I S A測量,相對於其相對應之未水解蛋白 質混合物,抗原性降低8 0 — 9 9%。 (請先閲讀背面之注意事項再填寫本頁) 訂- 經濟部中央標準局貝工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4规格(210X297公梦)-3 -111004 [57]申請專利範圍: 1. 一種蛋白質混合物之部份水解產物, 其中該蛋白質混合物係含有60至80重 量%之乳淸蛋白及40至20重量%之酪 蛋白,且該部份水解產物係具有 ⑴水解程度介於4至10%之間,(2>藉 由ELISA測量,相對於其相對應之未 水解蛋白質混合物,抗原性係降低 80-99%,及(3)平均分子量爲2,000, 最大分子量爲19,000 ,且以其莫耳質 量爲基準,其肽分佈係如下所示: 分子量(克/莫耳) %分子量分佈 MW> 5000 8.2 5000 > MW > 3000 14.5 3000 > MW > 2000 15.8 2000>MW> 1000 26.2 1000>MW> 500 17.8 MW> 500 17.5 該部份水解產物之製備係藉由於60至 90t:之溫度下先期預熱該蛋白質混合 物達10至50分鐘且於30至50C之溫 度及pH値介於6.5至8.0之條件下,令 該蛋白質混合物與一酶混合液於水溶 5. 性懸浮液中相接觸達2至6小時,以使 該蛋白質混合物之水解程度達4至 10%,其中該酶混合液係包含至少 1800USP胰蛋白酶單位/mg及至少 350USP胰凝乳蛋白酶/mg,且該胰蛋 10. 白酶對胰凝乳蛋白酶之USP單位比係 介於1.5至10之間,且隨後該酶混合 液之去活化係藉由於70至9(TC之溫度 下加熱該部份水解產物達5至20分鐘 ’或於110至140Ό之溫度下加熱該 15. 部份水解產物達30至60秒。 2.如申請專利範圍第丨項之部份水解產 物,其係具有藉由ELISA測量,相對 於其相對應之未水解蛋白質混合物, 抗原性降低85-99%。 一 8— ⑵ 3 3. 如申請專利範圍第〖項之部份水解產 物,其係具有藉由ELISA測量,相對 於其相對應之未水解蛋白質混合物, 抗原性降低90-99% » 4. 如申請專利範圍第丨項之部份水解產 5. 物,其係具有藉由ELISA測量,相對 於其相對應之未水解蛋白質混合物, 抗原性降低95-99%。 5. 如申請專利範圍第1項之部份水解產 物,其中該酶混合液之用量係基於混 10. 合物中蛋白質之重量爲介於0.4至 1.2%之間》 6. 如申請專利範圍第1項之部份水解產 物,其中於額外之步驟中係藉由蒸發 或噴霧乾燥以自該部份水解產物中除 15. 4 去水。 7. —種嬰兒配方食品,其係包含如申請 專利範圍第1項之部份水解產物,以 及慣用之碳水化合物,脂質,礦物質 和維生素。 8. 如申請專利範圍第7項之嬰兒配方食 品,其係經消毒滅菌》 9. 如申請專利範圍第7項之嬰兒配方食 品,其係經高溫蒸氣滅菌。 10. 如申請專利範圍第7項之嬰兒配方食 品’其係呈粉末之型式。 11. 如申請專利範圍第7項之嬰兒配方食 品’其係具有藉由ELISA測量,相對 户其相對應之未水解蛋白質混合物, k原性降低80-99%。 —9—
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/085,213 US5405637A (en) | 1993-06-30 | 1993-06-30 | Milk protein partial hydrolysate and infant formula containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW317487B true TW317487B (zh) | 1997-10-11 |
Family
ID=22190206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW083104127A TW317487B (zh) | 1993-06-30 | 1994-05-06 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5405637A (zh) |
| EP (1) | EP0631731B1 (zh) |
| JP (1) | JP3650420B2 (zh) |
| CN (1) | CN1044665C (zh) |
| AT (1) | ATE205056T1 (zh) |
| AU (1) | AU672697B2 (zh) |
| CA (1) | CA2126639C (zh) |
| DE (1) | DE69428165T2 (zh) |
| ES (1) | ES2160606T3 (zh) |
| PH (1) | PH30826A (zh) |
| TW (1) | TW317487B (zh) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405637A (en) * | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| US6274141B1 (en) * | 1995-02-28 | 2001-08-14 | Doyle W. Boatwright | Enzymatic dietary treatment for hydrolyzing BSA |
| US7094949B2 (en) | 1995-05-16 | 2006-08-22 | A2 Corporation Limited | Breeding and milking cows for milk free of β-casein A1 |
| US6570060B2 (en) | 1995-05-16 | 2003-05-27 | Mclachlan Corran Norman Stuart | Milk lacking β-casein A1 |
| ATE297125T1 (de) * | 1995-05-16 | 2005-06-15 | A2 Corp Ltd | Nahrungsmittel und herstellungsverfahren |
| US6432468B1 (en) * | 1995-05-30 | 2002-08-13 | Suntory Limited | Domestic fowl eggs having a high content of highly unsaturated fatty acid, their production process and their use |
| DE69621800T2 (de) * | 1996-09-06 | 2002-10-02 | Societe Des Produits Nestle S.A., Vevey | Induktion von Toleranz gegen Kuhmilch |
| NL1005037C2 (nl) * | 1997-01-17 | 1998-07-20 | Nl Zuivelonderzoek Inst | Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten. |
| SA98190002B1 (ar) * | 1997-03-28 | 2006-06-20 | ذي يونيفيرسيتي اوف تننيسي ريسيرش كوربوريشن | استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| DE19726868A1 (de) * | 1997-06-24 | 1999-01-07 | Mk Produktkontor Gmbh | Antioxidative Zusammensetzungen mit Süßmolkekonzentrat |
| CA2308436A1 (en) * | 1997-11-05 | 1999-05-14 | Biozone Laboratories, Inc. | Enhanced infant formula containing liposome encapsulated nutrients and agents |
| FR2771259B1 (fr) * | 1997-11-21 | 2000-01-28 | Nutriset | Aliment complet ou supplement nutritionnel stable vis a vis de l'oxydation, a haute valeur energetique, basse osmolalite, faible teneur en eau, son procede de preparation et ses utilisations |
| US6919314B1 (en) * | 1998-06-17 | 2005-07-19 | New Zealand Dairy Board | Bioactive whey protein hydrolysate |
| DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
| JP2002533693A (ja) | 1998-12-23 | 2002-10-08 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | 苦味応答のインヒビター |
| EP1034704A1 (en) * | 1999-03-12 | 2000-09-13 | Societe Des Produits Nestle S.A. | Nutritional composition intended for specific gastro-intestinal maturation in premature mammals |
| MXPA01010778A (es) * | 1999-04-29 | 2003-08-20 | Nestle Sa | Composicion para una formula para infantes, que tiene un bajo contenido de treonina. |
| GB9923048D0 (en) * | 1999-09-29 | 1999-12-01 | Nestle Sa | Composition comprising casein protein and whey protein |
| US6998259B1 (en) | 1999-05-20 | 2006-02-14 | Davisco Foods International | Enzymatic treatment of whey proteins for the production of antihypertensive peptides and the resulting products |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US6261624B1 (en) | 1999-07-14 | 2001-07-17 | North Carolina State University | Thermal and PH stable protein thickening agent and method of making the same |
| US6630320B1 (en) | 2000-05-08 | 2003-10-07 | Devisco Foods International, Inc. | Treatment of hypertension in mammals with hydrolyzed whey proteins |
| US6551636B2 (en) | 1999-07-23 | 2003-04-22 | Novozymes A/S | Modification of foaming properties of proteins |
| WO2001017320A1 (en) * | 1999-08-27 | 2001-03-08 | Lex Kosowsky | Current carrying structure using voltage switchable dielectric material |
| WO2001070047A1 (en) * | 2000-03-24 | 2001-09-27 | Société des Produits Nestlé S.A. | Nutritional composition comprising hydrolysed protein |
| RU2193327C2 (ru) * | 2000-07-04 | 2002-11-27 | Вологодская государственная молочно-хозяйственная академия им. Н.В.Верещагина | Способ производства пахты низколактозной с гидролизованным белком |
| US6592863B2 (en) * | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
| ATE372689T1 (de) * | 2001-07-18 | 2007-09-15 | Dsm Ip Assets Bv | Verfahren zur hydrolyse von milcheiweissen |
| EP1281325A1 (en) * | 2001-07-30 | 2003-02-05 | Societe Des Produits Nestle S.A. | Nutritional composition preventing bacterial overgrowth |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US20060039958A1 (en) * | 2003-05-28 | 2006-02-23 | Monosolrx, Llc. | Multi-layer films having uniform content |
| JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−18誘導剤 |
| DK1443825T3 (da) | 2001-11-06 | 2009-02-02 | Novozymes North America Inc | Modificerede valleproteinsammensætninger, der har forbedrede skumningsegenskaber |
| WO2003071875A1 (en) * | 2002-02-21 | 2003-09-04 | Land O'lakes, Inc. | Method of preparing a milk polar lipid enriched concentrate and a sphingolipid enriched concentrate |
| US7618648B2 (en) * | 2002-07-01 | 2009-11-17 | Unilever Bestfoods, North America Division Of Conopco, Inc. | Satiety inducing composition |
| PT2287288E (pt) | 2002-07-09 | 2012-12-10 | Baxter Int | Meio isento de proteína animal para cultura de células |
| TWI317636B (en) * | 2002-11-22 | 2009-12-01 | Meiji Dairies Corp | Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress |
| US7261911B2 (en) * | 2002-12-19 | 2007-08-28 | Luebbers Steven T | Aseptically packaged, extensively hydrolyzed, liquid nutritional formula and method for making it |
| US7399496B2 (en) * | 2003-02-07 | 2008-07-15 | Glanbia Nutritionals (Ireland) Limited | Hydrolyzed whey protein compositions |
| US8877232B2 (en) | 2003-06-20 | 2014-11-04 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
| WO2005013708A1 (en) * | 2003-07-15 | 2005-02-17 | Dsm Ip Assets B.V. | Powderous formulations of fat-soluble active ingredients |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| US8252314B2 (en) * | 2004-09-24 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Hypoallergenic composition |
| JP5160229B2 (ja) | 2004-09-30 | 2013-03-13 | モノソル・アールエックス・エルエルシー | 均一の成分を有する多層フィルム |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| ES2381118T3 (es) * | 2004-12-23 | 2012-05-23 | Campina Nederland Holding B.V. | Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso |
| EP1841333A1 (en) * | 2005-01-14 | 2007-10-10 | Solae, Llc | Soy protein for infant formula |
| WO2006130738A2 (en) | 2005-06-01 | 2006-12-07 | Hill's Pet Nutrition, Inc. | Methods for enhancing palatability of compositions for animal consumption |
| US7618669B2 (en) * | 2005-06-01 | 2009-11-17 | Mead Johnson Nutrition Company | Low-lactose partially hydrolyzed infant formula |
| US20060286208A1 (en) * | 2005-06-01 | 2006-12-21 | Nagendra Rangavajla | Methods for producing protein partial hydrolysates and infant formulas containing the same |
| US10130113B2 (en) * | 2005-06-09 | 2018-11-20 | Colgate-Palmolive Company | Composition and method for providing glutamine |
| US7455872B2 (en) * | 2005-06-20 | 2008-11-25 | Redpoint Bio Corporation | Compositions and methods for producing a salty taste in foods or beverages |
| US7452563B2 (en) * | 2005-06-20 | 2008-11-18 | Redpoint Bio Corporation | Compositions and methods for producing flavored seasonings that contain reduced quantities of common salt |
| PT1898724E (pt) * | 2005-07-01 | 2010-11-26 | Nutricia Nv | Nutrição infantil com proteínas hidrolisadas |
| US8431531B2 (en) * | 2005-11-30 | 2013-04-30 | Campina Nederland Holding B.V. | Methods for stimulating glucagon-like peptide-1(GLP-1) secretion and treatments comprising same |
| WO2007077217A2 (en) | 2006-01-04 | 2007-07-12 | Baxter International Inc. | Oligopeptide-free cell culture media |
| US7875303B2 (en) * | 2006-03-31 | 2011-01-25 | Kraft Foods Global Brands Llc | Protein system and food products including same |
| WO2007113279A1 (en) * | 2006-03-31 | 2007-10-11 | Dsm Ip Assets B.V. | Process for the hydrolysis of milk proteins |
| ES2529237T3 (es) * | 2006-12-20 | 2015-02-18 | Dupont Nutrition Biosciences Aps | Hidrolizados de proteínas de la leche con potencial inmunogénico reducido |
| JP5622580B2 (ja) * | 2007-11-07 | 2014-11-12 | エム・ジェイ・エヌ ユー.エス. ホールディングス リミテッド ライアビリティー カンパニー | タンパク質を含まない、加水分解された乳児用調合乳の苦味を減少させ風味を改善する方法 |
| CA2706636A1 (en) * | 2007-11-26 | 2009-06-04 | Nestec S.A. | Age-tailored nutrition system for infants |
| DE102007063429A1 (de) * | 2007-12-19 | 2009-06-25 | Animox Gmbh | Reaktives Additiv aus eiweißhaltigen Rohstoffen und Abprodukten tierischer oder pflanzlicher Herkunft |
| WO2009085388A2 (en) | 2007-12-20 | 2009-07-09 | Abbott Laboratories | Stable nutritional powder |
| US8361534B2 (en) * | 2007-12-20 | 2013-01-29 | Abbott Laboratories | Stable nutritional powder |
| DK2413720T3 (da) * | 2009-04-02 | 2019-09-30 | Novozymes As | Fremgangsmåde til fremstilling af et mælkebaseret proteinhydrolysat |
| EP2258208A1 (en) * | 2009-06-02 | 2010-12-08 | University of Limerick | Protein Product With Modified Antigenicity |
| EP2436389A1 (en) | 2010-10-01 | 2012-04-04 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| EP2489281A1 (en) | 2011-02-17 | 2012-08-22 | University of Limerick | A casein hydrolysate |
| FI124323B (fi) | 2011-02-18 | 2014-06-30 | Valio Oy | Maitopohjainen tuote ja menetelmä sen valmistamiseksi |
| US9474298B2 (en) | 2011-10-11 | 2016-10-25 | Mead Johnson Nutrition Company | Partially hydrolyzed casein-whey nutritional compositions for reducing the onset of allergies |
| WO2013056038A2 (en) * | 2011-10-14 | 2013-04-18 | Abbott Laboratories | Sterilized liquid protein supplement |
| SG11201406136XA (en) * | 2012-05-24 | 2014-11-27 | Abbott Lab | Sterilized liquid protein supplement including a solubility enhancing nutritional protein |
| DK2730170T3 (en) | 2012-11-13 | 2016-05-30 | Dmk Deutsches Milchkontor Gmbh | Allergen-free food compositions |
| CN103182248A (zh) * | 2013-01-09 | 2013-07-03 | 大连海洋大学 | 超滤、电渗析复合技术降低贝类提取液中重金属的方法 |
| CN103966292A (zh) * | 2013-01-31 | 2014-08-06 | 中国食品发酵工业研究院 | 一种过敏原部分消除的适度水解酪蛋白肽工业化制造方法及其应用 |
| US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
| US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
| US9289461B2 (en) * | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
| US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
| US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
| US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
| WO2014163486A1 (en) * | 2013-04-03 | 2014-10-09 | N.V. Nutricia | Process and system for preparing dry milk formulae |
| US20150157048A1 (en) * | 2013-12-11 | 2015-06-11 | Mead Johnson Nutrition Company | Nutritional compositions containing stearidonic acid and uses thereof |
| US10639334B2 (en) * | 2014-01-07 | 2020-05-05 | Mead Johnson Nutrition Company | Pediatric nutritional composition with milk peptides for healthy growth and development |
| NO339988B1 (en) | 2015-05-29 | 2017-02-27 | Calanus As | Novel marine protein hydrolysates and uses thereof |
| EP3167895A1 (en) * | 2015-11-10 | 2017-05-17 | University College Dublin | A dietary supplement comprising beta-glucan and casein hydrolysate for improving health and growth performance in a mammal |
| WO2017102258A1 (en) * | 2015-12-18 | 2017-06-22 | Nestec S.A. | Heat sterilized high protein compositions with hydrolyzed protein from a continuous process with at least one endopeptidase |
| JP7102347B2 (ja) | 2016-03-24 | 2022-07-19 | エルガン ファーマ リミテッド | 胃内容排出を増進させるインスリンの使用 |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US10980269B2 (en) * | 2016-12-12 | 2021-04-20 | Mead Johnson Nutrition Company | Protein hydrolysates and methods of making same |
| CN107927196A (zh) * | 2017-12-11 | 2018-04-20 | 哈尔滨商业大学 | 具有益生菌增殖效果的乳蛋白水解婴幼儿配方粉的制备方法 |
| KR20200108829A (ko) | 2018-01-16 | 2020-09-21 | 프리슬랜드캄피나 네덜란드 비.브이. | 저알레르기성 영아용 조제식 및 이의 제조 방법 |
| KR20240093867A (ko) | 2021-10-22 | 2024-06-24 | 마아즈, 인코오포레이티드 | 식품 조성물로서 사용하기 위한 뉴클레오티드 및 올리고사카라이드 |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| CN115633727B (zh) * | 2022-09-09 | 2024-07-12 | 黑龙江飞鹤乳业有限公司 | 水解蛋白组合物的制备方法 |
| TW202423299A (zh) | 2022-10-07 | 2024-06-16 | 美商瑪斯公司 | 小型犬食物組合物 |
| EP4687479A1 (en) | 2023-04-06 | 2026-02-11 | Mars, Incorporated | Low fat hypoallergenic food composition for companion animals |
| EP4449875A1 (en) | 2023-04-18 | 2024-10-23 | Mars, Incorporated | Composition for use for improving or preserving mental health in canine |
| CN116725116A (zh) * | 2023-06-27 | 2023-09-12 | 黑龙江飞鹤乳业有限公司 | 乳清蛋白制备方法 |
| EP4529775A1 (en) | 2023-09-29 | 2025-04-02 | Mars, Incorporated | Method for improving memory consolidation in canine |
| WO2026003207A1 (en) | 2024-06-27 | 2026-01-02 | Mars, Incorporated | Low-fat food composition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200849C (zh) * | ||||
| DE237322C (zh) * | ||||
| CH636248A5 (fr) * | 1979-03-09 | 1983-05-31 | Nestle Sa | Procede de preparation d'un hydrolysat de proteines purifie. |
| ZA86415B (en) * | 1985-01-29 | 1986-09-24 | Abbott Lab | Enteral nutritional hypoallergenic formula |
| DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
| FR2608051B1 (fr) * | 1986-12-15 | 1989-04-07 | Bellon Labor Sa Roger | Procede de fabrication d'un hydrolysat enzymatique de proteines riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique |
| DD273543A3 (de) * | 1987-09-14 | 1989-11-22 | Univ Rostock | Verfahren zur herstellung von saeuglings- und diaetnahrungen mit hypoantigener, bifidogener wirkung |
| CH672230A5 (zh) * | 1987-10-15 | 1989-11-15 | Nestle Sa | |
| JPH0616824B2 (ja) * | 1987-12-16 | 1994-03-09 | 三協食品工業株式会社 | 乳蛋白性界面活性剤とその製造方法 |
| EP0321603A1 (fr) * | 1987-12-23 | 1989-06-28 | Societe Des Produits Nestle S.A. | Procédé de préparation d'un hydrolysat de protéines de lactosérum et d'un aliment hypoallergéniques |
| JPH0779639B2 (ja) * | 1988-05-06 | 1995-08-30 | 株式会社片山化学工業研究所 | クリーム状乳加工品の品質改良剤 |
| FR2634104B1 (fr) * | 1988-07-18 | 1991-10-18 | Union Coop Agricole | Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant |
| FR2644986B1 (fr) * | 1989-03-31 | 1991-06-21 | Union Coop Agricole | Hydrolysat partiel des proteines de lactoserum exempt de lactoglobulines et procede enzymatique pour son obtention |
| US4973488A (en) * | 1989-05-17 | 1990-11-27 | Excelpro, Inc. | Hydrolyzed proteinaceous milk solid and process of making |
| US5223284A (en) * | 1991-05-22 | 1993-06-29 | Washington University | Products and methods for treating colic |
| WO1993004593A1 (en) * | 1991-08-30 | 1993-03-18 | Teagasc, The Agriculture And Food Development Authority | Hypoallergenic whey protein hydrolysate |
| DK71292D0 (zh) * | 1992-05-27 | 1992-05-27 | Novo Nordisk As | |
| US5405637A (en) * | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
-
1993
- 1993-06-30 US US08/085,213 patent/US5405637A/en not_active Expired - Lifetime
-
1994
- 1994-05-06 TW TW083104127A patent/TW317487B/zh not_active IP Right Cessation
- 1994-06-23 CA CA002126639A patent/CA2126639C/en not_active Expired - Fee Related
- 1994-06-27 PH PH48527A patent/PH30826A/en unknown
- 1994-06-27 JP JP17737394A patent/JP3650420B2/ja not_active Expired - Fee Related
- 1994-06-28 AU AU65988/94A patent/AU672697B2/en not_active Ceased
- 1994-06-30 DE DE69428165T patent/DE69428165T2/de not_active Expired - Lifetime
- 1994-06-30 AT AT94110229T patent/ATE205056T1/de not_active IP Right Cessation
- 1994-06-30 CN CN94106575A patent/CN1044665C/zh not_active Expired - Fee Related
- 1994-06-30 EP EP94110229A patent/EP0631731B1/en not_active Expired - Lifetime
- 1994-06-30 ES ES94110229T patent/ES2160606T3/es not_active Expired - Lifetime
- 1994-11-21 US US08/342,977 patent/US5589357A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2126639A1 (en) | 1994-12-31 |
| EP0631731A1 (en) | 1995-01-04 |
| US5405637A (en) | 1995-04-11 |
| JP3650420B2 (ja) | 2005-05-18 |
| US5589357A (en) | 1996-12-31 |
| AU672697B2 (en) | 1996-10-10 |
| CA2126639C (en) | 2007-11-06 |
| CN1105818A (zh) | 1995-08-02 |
| JPH0723717A (ja) | 1995-01-27 |
| PH30826A (en) | 1997-10-17 |
| ATE205056T1 (de) | 2001-09-15 |
| ES2160606T3 (es) | 2001-11-16 |
| CN1044665C (zh) | 1999-08-18 |
| DE69428165D1 (de) | 2001-10-11 |
| DE69428165T2 (de) | 2002-05-16 |
| AU6598894A (en) | 1995-01-12 |
| EP0631731B1 (en) | 2001-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW317487B (zh) | ||
| AU765986B2 (en) | Composition for an infant formula having a low threonine content | |
| RU2407399C2 (ru) | Способ получения частичных белковых гидролизатов и молочные смеси, содержащие их | |
| CZ20021135A3 (cs) | Prostředek pro kojeneckou výľivu | |
| JP6875421B2 (ja) | 乳清タンパク質ミセルを含む乳清タンパク質及びカゼイン供給源を有する加熱殺菌された高タンパク質経腸組成物 | |
| JP2011184314A (ja) | 筋肉萎縮防止剤 | |
| JPH09507123A (ja) | 乳清タンパク質を主成分とする乳児用ミルク食品 | |
| CA2873127A1 (en) | Sterilized liquid protein supplement including a solubility enhancing nutritional protein | |
| CA3025998A1 (en) | Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein | |
| AU2003298196A1 (en) | Nutritional formula comprising L(+) lactic acid | |
| CN113365508A (zh) | 具有高等电蛋白质的蛋白质组合物 | |
| McSweeney et al. | Nutritional formulae for infants and young children | |
| CN102573880B (zh) | 脂肪累积抑制剂 | |
| JP7749308B2 (ja) | 乳児用栄養組成物 | |
| BR112019010189A2 (pt) | composições nutricionais colheráveis altamente proteicas esterilizadas por calor com proteína do soro do leite que compreendem micelas de proteína do soro do leite e uma fonte de caseína | |
| WO2012121612A1 (en) | Method of manufacture of an edible composition | |
| AU2026200303A1 (en) | Protein compositions with high isoelectric proteins | |
| Kuntz | Concentrating on whey protein isolate | |
| HK1119375A (zh) | 生產蛋白質部分水解物的方法以及含有上述蛋白質部分水解物的嬰兒配方 | |
| NZ623027B2 (en) | Sterilized liquid protein supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |